Plain-English translation of NCT07130032 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This trial is testing a combination of three medications: anti-PD-1/PD-L1 antibodies, bevacizumab, and metronomic cyclophosphamide. The study involves people with advanced (metastatic) non-small cell lung cancer or melanoma who have already been treated with immunotherapy but whose cancer continued to grow. The goal is to see if using these three treatments together can help fight cancers that have become resistant to immunotherapy alone.
When cancers stop responding to immunotherapy, it's because the tumor develops ways to hide from the immune system. This medication combination was designed to attack that resistance from multiple angles at once—helping the immune system see the cancer better, improving blood flow to tumors, and boosting immune cell activity.
You likely qualify if…
You likely don't qualify if…
You would receive the three-drug combination treatment until your cancer stops responding or side effects become too difficult to manage. While the exact visit schedule isn't detailed here, typical cancer immunotherapy trials involve regular clinic visits for treatment infusions, blood tests, and imaging scans to monitor how your cancer is responding. Your healthcare team will watch closely for any side effects and adjust your treatment as needed.
AI-generated summary from trial data · Jun 7, 2026 · Not medical advice
Russia